XINT.ST Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 11:29):

Stats
Today's Volume	71 165.00
Average Volume	261 387
Market Cap	150.26M
EPS	SEK-0.0265 ( 2023-09-30 )
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-2.04
ATR14	SEK0.00600 (2.26%)

Xintela AB (publ) Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Xintela AB (publ) Financials

Annual	2023
Revenue:	SEK78 000.00
Gross Profit:	SEK-3.69M (-4 728.21 %)
EPS:	SEK-0.130

Q4	2023
Revenue:	SEK78 000.00
Gross Profit:	SEK-867 000 (-1 111.54 %)
EPS:	SEK-0.0279

Q3	2023
Revenue:	SEK0
Gross Profit:	SEK-952 000 (0.00 %)
EPS:	SEK-0.0200

Q2	2023
Revenue:	SEK0
Gross Profit:	SEK-933 000 (0.00 %)
EPS:	SEK-0.0598

Financial Reports:

No articles found.

Xintela AB (publ)

Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. It is also developing XSTEM a stem cell product that is in clinical development phase for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; and EQSTEM, a stem cell product for the treatment of joint diseases in horses, as well as focuses on the preclinical development of therapeutic antibodies for aggressive cancers, including brain tumor glioblastoma and triple negative breast cancer. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.